Antibody-Drug Conjugates and Immunotoxins (Record no. 95414)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04080nam a22004695i 4500 |
| 001 - CONTROL NUMBER | |
| control field | 978-1-4614-5456-4 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | DE-He213 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20140220082820.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 121212s2013 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781461454564 |
| -- | 978-1-4614-5456-4 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-1-4614-5456-4 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC261-271 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MJCL |
| Source | bicssc |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MED062000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 614.5999 |
| Edition number | 23 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Phillips, Gail Lewis. |
| Relator term | editor. |
| 245 10 - TITLE STATEMENT | |
| Title | Antibody-Drug Conjugates and Immunotoxins |
| Medium | [electronic resource] : |
| Remainder of title | From Pre-Clinical Development to Therapeutic Applications / |
| Statement of responsibility, etc | edited by Gail Lewis Phillips. |
| 264 #1 - | |
| -- | New York, NY : |
| -- | Springer New York : |
| -- | Imprint: Springer, |
| -- | 2013. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | IX, 372 p. 88 illus., 45 illus. in color. |
| Other physical details | online resource. |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 347 ## - | |
| -- | text file |
| -- | |
| -- | rda |
| 490 1# - SERIES STATEMENT | |
| Series statement | Cancer Drug Discovery and Development |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Antibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins -- Antibody-Drug Conjugate Development -- Components of ADC Development: Assay Methodologies and Challenges -- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates -- Predictive Biomarkers for Antibody-Drug Conjugates -- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates -- Linker Technology and Impact of Linker Design on ADC Properties -- Antibody-drug conjugates for the treatment of B-cell malignancies -- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies -- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies -- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer -- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE) -- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer -- EphA2 Immunoconjugate -- Anti-PSMA Antibody-Drug Conjugates -- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine -- Studies on the Metabolism of Antibody-Drug Conjugates -- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu -- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors -- Index. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | The concept of delivering ‘magic bullets’ to treat diseases was first proposed by Paul Erlich in the early 1900’s. The realization of this concept for the treatment of cancer occurred in the late 1990’s with the approval of monoclonal antibody therapies. The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy. ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics. More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use. This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologic and solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Oncology. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Monoclonal antibodies. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Cancer Research. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biomedicine general. |
| 650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Antibodies. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Printed edition: |
| International Standard Book Number | 9781461454557 |
| 830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE | |
| Uniform title | Cancer Drug Discovery and Development |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://dx.doi.org/10.1007/978-1-4614-5456-4 |
| 912 ## - | |
| -- | ZDB-2-SME |
No items available.